Exclusive: Bristol Meyers Squibb's new CEO on CAR-T pipeline and future cuts

Bristol CEO Christopher Boerner was bullish about the potential for CAR-T beyond cancer, taking on autoimmune disorders like multiple sclerosis and lupus.

April 26, 2024 Check out STAT+

Sponsored By

Courtesy Bristol Myers Squibb STAT+ | Amid layoffs and a hit to earnings, Bristol's new CEO shares his vision for the future Despite layoffs and a hit to earnings, CEO Christopher Boerner was optimistic about the company's prospects in an interview with STAT. By Matthew Herper Opinion: Balancing hope and reality: The promise and peril of blood-based colorectal cancer screening A blood test to detect colorectal cancer would be a step toward more widespread screening. But it can't do what colonoscopy does. By Folasade P. May Opinion: Bashing accelerated approval isn't supported by the data In-depth survival data question a new study suggesting that accelerated approval drugs often do not improve clinical outcomes. By Peter J. Pitts and Timothy R. Franson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser